文献速递术前评估与围术期医学气道管理

氯胺酮作为创伤患者快速序贯诱导剂:一项系统综述

Ketamine as a Rapid Sequence Induction Agent in the Trauma Population: A Systematic Review.
PubMed 文献 · Anesth Analg · 2019-01-01

该系统综述检索了PubMed、Embase和Cochrane图书馆,纳入4项比较氯胺酮与其他诱导剂用于成人创伤患者快速序贯诱导的研究。未发现氯胺酮与其他诱导剂在死亡率、住院时间或输血量方面存在显著差异,但不能排除临床相关的获益或危害。

要点

  • 氯胺酮与其他诱导剂在创伤患者快速序贯诱导中死亡率无显著差异。
  • 氯胺酮组与对照组在住院时间和输血量方面无显著差异。
  • 纳入研究极少且偏倚风险不一,无法进行有意义的荟萃分析。

核心结论

  • 与其它诱导剂相比,氯胺酮用于创伤患者快速序贯诱导未显示死亡率、住院时间或输血量方面的显著差异,但临床相关获益或危害不能排除。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Cochrane图书馆(2016年9月19日),纳入4项比较氯胺酮与另一种诱导剂(依托咪酯、丙泊酚、硫喷妥钠或咪达唑仑)用于成人创伤患者快速序贯诱导的研究。

主要发现

  • 1976年队列研究比较硫喷妥钠(n=26)与氯胺酮(n=14),主要结局为输血量,无显著差异,偏倚风险为严重。
  • 2009年随机对照试验比较依托咪酯(n=57)与氯胺酮(n=47),28天死亡率无显著差异(OR 0.8 [0.4-2.0]),偏倚风险低。
  • 2015年队列研究比较依托咪酯(n=116)与氯胺酮(n=145),院内死亡率无显著差异(OR 1.11 [0.38-3.27]),偏倚风险中等。
  • 2017年队列研究比较依托咪酯(n=526)与氯胺酮(n=442),院内死亡率无显著差异(OR 1.41 [0.91-2.16]),偏倚风险中等。
  • 2017年研究还报告伤后48小时内输血单位数(OR 1.14 [0.87-1.49])和住院时间(OR 1.1 [0.95-1.27]),均无显著差异。

临床怎么用

  • 现有证据不支持在创伤患者快速序贯诱导中常规优先选择氯胺酮而非其他诱导剂。
  • 临床决策需结合患者血流动力学状态及诱导剂特性个体化选择。

局限性

  • 比较创伤患者快速序贯诱导剂的 study 极少,仅纳入4项研究。
  • 研究间偏倚风险不一(低至严重),且无法进行有意义的荟萃分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The choice of drug used to facilitate endotracheal intubation in trauma patients during rapid sequence induction (RSI) may have an impact on survival. Ketamine is commonly used in the hemodynamically unstable trauma patient although it has been associated with side effects. This review sought to investigate whether ketamine should be preferred over other induction agents for RSI in trauma patients. PubMed, Embase, and the Cochrane Library were systematically searched on September 19, 2016 for studies reporting RSI of adult trauma patients with ketamine compared with another induction agent (etomidate, propofol, thiopental, or midazolam). No language restrictions were applied. The primary outcome was 30-day mortality, and secondary outcomes included information on blood transfusions, length of hospital stay, and hospital mortality. Risk of bias was assessed using the Cochrane Risk of Bias assessment tool for randomized trials and the Risk of Bias in Non-Randomized Studies of Interventions for nonrandomized studies of intervention. A total of 4 studies were included. A cohort study from 1976 compared thiopental (n = 26) with ketamine (n = 14) for RSI in trauma patients. The primary outcome was number of blood transfusions, and no significant difference was found. Risk of bias was judged to be serious. A randomized controlled trial from 2009 compared etomidate (n = 57) with ketamine (n = 47) and found no significant difference in 28-day mortality (odds ratio [OR], 0.8 [0.4-2.0]). The trial was judged to have a low risk of bias. Two cohort studies from 2015 and 2017 also compared etomidate (n = 116 and n = 526) with ketamine (n = 145 and n = 442). No significant difference in hospital mortality between the groups was observed (OR, 1.11 [0.38-3.27] and OR, 1.41 [0.91-2.16], respectively). Both studies were judged to have a moderate risk of bias, thus excluding the possibility of a meaningful meta-analysis. The study from 2017 also reported number of units of blood transfused during the first 48 hours after trauma and length of hospital stay. No significant differences were observed (OR, 1.14 [0.87-1.49] and OR, 1.1 [0.95-1.27], respectively). Extremely few studies have compared induction agents for RSI in trauma patients. No significant differences have been found in mortality, length of hospital stay, or number of blood transfusions after induction with ketamine compared to other induction agents, but a clinically relevant benefit or harm cannot be excluded.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Baekgaard JS, Eskesen TG, Sillesen M, et al. Ketamine as a Rapid Sequence Induction Agent in the Trauma Population: A Systematic Review. Anesth Analg. 2019. PMID: 29944524. doi:10.1213/ANE.0000000000003568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。